Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

60 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Improving vaccine policy making: A dose of reality.
Reiss DR, Offit PA. Reiss DR, et al. Vaccine. 2020 Feb 28;38(10):2273-2274. doi: 10.1016/j.vaccine.2020.01.036. Epub 2020 Feb 5. Vaccine. 2020. PMID: 32033846 No abstract available.
French mandatory vaccine policy.
Yang YT, Reiss DR. Yang YT, et al. Among authors: reiss dr. Vaccine. 2018 Mar 7;36(11):1323-1325. doi: 10.1016/j.vaccine.2018.01.073. Epub 2018 Feb 6. Vaccine. 2018. PMID: 29426655 No abstract available.
The law and vaccine resistance.
Reiss DR. Reiss DR. Science. 2019 Feb 22;363(6429):795. doi: 10.1126/science.aax0019. Science. 2019. PMID: 30792277 No abstract available.
When Are Vaccine Mandates Appropriate?
Shachar C, Reiss DR. Shachar C, et al. Among authors: reiss dr. AMA J Ethics. 2020 Jan 1;22(1):E36-42. doi: 10.1001/amajethics.2020.36. AMA J Ethics. 2020. PMID: 31958389 Free article.
CDC's new rule to track and quarantine travellers.
Yang YT, Reiss DR. Yang YT, et al. Among authors: reiss dr. J Travel Med. 2017 Sep 1;24(6). doi: 10.1093/jtm/tax070. J Travel Med. 2017. PMID: 29088485 No abstract available.
Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
Omer SB, Benjamin RM, Brewer NT, Buttenheim AM, Callaghan T, Caplan A, Carpiano RM, Clinton C, DiResta R, Elharake JA, Flowers LC, Galvani AP, Lakshmanan R, Maldonado YA, McFadden SM, Mello MM, Opel DJ, Reiss DR, Salmon DA, Schwartz JL, Sharfstein JM, Hotez PJ. Omer SB, et al. Among authors: reiss dr. Lancet. 2021 Dec 11;398(10317):2186-2192. doi: 10.1016/S0140-6736(21)02507-1. Epub 2021 Nov 15. Lancet. 2021. PMID: 34793741 Free PMC article. Review.
Uncoupling vaccination from politics: a call to action.
Sharfstein JM, Callaghan T, Carpiano RM, Sgaier SK, Brewer NT, Galvani AP, Lakshmanan R, McFadden SM, Reiss DR, Salmon DA, Hotez PJ; Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Sharfstein JM, et al. Among authors: reiss dr. Lancet. 2021 Oct 2;398(10307):1211-1212. doi: 10.1016/S0140-6736(21)02099-7. Epub 2021 Sep 16. Lancet. 2021. PMID: 34537104 Free PMC article. No abstract available.
Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
Commissioners of the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Commissioners of the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet. 2021 Mar 27;397(10280):1165-1167. doi: 10.1016/S0140-6736(21)00372-X. Epub 2021 Feb 24. Lancet. 2021. PMID: 33639088 No abstract available.
Employer-Mandated Vaccination for COVID-19.
Rothstein MA, Parmet WE, Reiss DR. Rothstein MA, et al. Among authors: reiss dr. Am J Public Health. 2021 Jun;111(6):1061-1064. doi: 10.2105/AJPH.2020.306166. Epub 2021 Feb 4. Am J Public Health. 2021. PMID: 33539177 Free PMC article. No abstract available.
Quantitative proteomics in laser capture microdissected sleep nuclei from rat brain.
Miller RA, Winrow CJ, Spellman DS, Song Q, Reiss DR, Conway JP, Taylor RR, Coleman PJ, Hendrickson RC, Renger JJ. Miller RA, et al. Among authors: reiss dr. J Neurogenet. 2014 Mar-Jun;28(1-2):136-45. doi: 10.3109/01677063.2014.883389. Epub 2014 Mar 3. J Neurogenet. 2014. PMID: 24579665 Free PMC article.
Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators.
Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, Renger JJ, Winrow CJ. Ramirez AD, et al. Among authors: reiss dr. Front Neurosci. 2013 Dec 24;7:254. doi: 10.3389/fnins.2013.00254. eCollection 2013. Front Neurosci. 2013. PMID: 24399926 Free PMC article.
Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).
Mercer SP, Roecker AJ, Garson S, Reiss DR, Meacham Harrell C, Murphy KL, Bruno JG, Bednar RA, Lemaire W, Cui D, Cabalu TD, Tang C, Prueksaritanont T, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Mercer SP, et al. Among authors: reiss dr. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6620-4. doi: 10.1016/j.bmcl.2013.10.045. Epub 2013 Oct 30. Bioorg Med Chem Lett. 2013. PMID: 24215892
Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.
Layton ME, Kelly MJ 3rd, Rodzinak KJ, Sanderson PE, Young SD, Bednar RA, Dilella AG, McDonald TP, Wang H, Mosser SD, Fay JF, Cunningham ME, Reiss DR, Fandozzi C, Trainor N, Liang A, Lis EV, Seabrook GR, Urban MO, Yergey J, Koblan KS. Layton ME, et al. Among authors: reiss dr. ACS Chem Neurosci. 2011 Jul 20;2(7):352-62. doi: 10.1021/cn200013d. Epub 2011 Apr 15. ACS Chem Neurosci. 2011. PMID: 22816022 Free PMC article.
Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ, McGaughey GB, Bednar RA, Lemaire W, Doran SM, Fox SV, Garson SL, Gotter AL, Harrell CM, Reiss DR, Cabalu TD, Cui D, Prueksaritanont T, Stevens J, Tannenbaum PL, Ball RG, Stellabott J, Young SD, Hartman GD, Winrow CJ, Renger JJ. Coleman PJ, et al. Among authors: reiss dr. ChemMedChem. 2012 Mar 5;7(3):415-24, 337. doi: 10.1002/cmdc.201200025. Epub 2012 Feb 3. ChemMedChem. 2012. PMID: 22307992
Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Winrow CJ, et al. Among authors: reiss dr. Neuropharmacology. 2012 Feb;62(2):978-87. doi: 10.1016/j.neuropharm.2011.10.003. Epub 2011 Oct 18. Neuropharmacology. 2012. PMID: 22019562
Discovery of a pharmacologically active antagonist of the two-pore-domain potassium channel K2P9.1 (TASK-3).
Coburn CA, Luo Y, Cui M, Wang J, Soll R, Dong J, Hu B, Lyon MA, Santarelli VP, Kraus RL, Gregan Y, Wang Y, Fox SV, Binns J, Doran SM, Reiss DR, Tannenbaum PL, Gotter AL, Meinke PT, Renger JJ. Coburn CA, et al. Among authors: reiss dr. ChemMedChem. 2012 Jan 2;7(1):123-33. doi: 10.1002/cmdc.201100351. Epub 2011 Sep 14. ChemMedChem. 2012. PMID: 21916012
TASK-3 as a potential antidepressant target.
Gotter AL, Santarelli VP, Doran SM, Tannenbaum PL, Kraus RL, Rosahl TW, Meziane H, Montial M, Reiss DR, Wessner K, McCampbell A, Stevens J, Brunner JI, Fox SV, Uebele VN, Bayliss DA, Winrow CJ, Renger JJ. Gotter AL, et al. Among authors: reiss dr. Brain Res. 2011 Oct 6;1416:69-79. doi: 10.1016/j.brainres.2011.08.021. Epub 2011 Aug 16. Brain Res. 2011. PMID: 21885038 Free PMC article.
Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Winrow CJ, et al. Among authors: reiss dr. J Neurogenet. 2011 Mar;25(1-2):52-61. doi: 10.3109/01677063.2011.566953. Epub 2011 Apr 8. J Neurogenet. 2011. PMID: 21473737
Indazole derivatives as novel bradykinin B1 receptor antagonists.
Bodmer-Narkevitch V, Anthony NJ, Cofre V, Jolly SM, Murphy KL, Ransom RW, Reiss DR, Tang C, Prueksaritanont T, Pettibone DJ, Bock MG, Kuduk SD. Bodmer-Narkevitch V, et al. Among authors: reiss dr. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7011-4. doi: 10.1016/j.bmcl.2010.09.121. Epub 2010 Sep 29. Bioorg Med Chem Lett. 2010. PMID: 20971001
Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat.
Coleman PJ, Schreier JD, Roecker AJ, Mercer SP, McGaughey GB, Cox CD, Hartman GD, Harrell CM, Reiss DR, Doran SM, Garson SL, Anderson WB, Tang C, Prueksaritanont T, Winrow CJ, Renger JJ. Coleman PJ, et al. Among authors: reiss dr. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4201-5. doi: 10.1016/j.bmcl.2010.05.047. Epub 2010 May 25. Bioorg Med Chem Lett. 2010. PMID: 20610153
Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, Roecker AJ, Mercer SP, Bednar RA, Lemaire W, Bruno JG, Reiss DR, Harrell CM, Murphy KL, Garson SL, Doran SM, Prueksaritanont T, Anderson WB, Tang C, Roller S, Cabalu TD, Cui D, Hartman GD, Young SD, Koblan KS, Winrow CJ, Renger JJ, Coleman PJ. Cox CD, et al. Among authors: reiss dr. J Med Chem. 2010 Jul 22;53(14):5320-32. doi: 10.1021/jm100541c. J Med Chem. 2010. PMID: 20565075
Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists.
Melamed JY, Zartman AE, Kett NR, Gotter AL, Uebele VN, Reiss DR, Condra CL, Fandozzi C, Lubbers LS, Rowe BA, McGaughey GB, Henault M, Stocco R, Renger JJ, Hartman GD, Bilodeau MT, Trotter BW. Melamed JY, et al. Among authors: reiss dr. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4700-3. doi: 10.1016/j.bmcl.2010.04.143. Epub 2010 May 5. Bioorg Med Chem Lett. 2010. PMID: 20510609
Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice.
Uebele VN, Gotter AL, Nuss CE, Kraus RL, Doran SM, Garson SL, Reiss DR, Li Y, Barrow JC, Reger TS, Yang ZQ, Ballard JE, Tang C, Metzger JM, Wang SP, Koblan KS, Renger JJ. Uebele VN, et al. Among authors: reiss dr. J Clin Invest. 2009 Jun;119(6):1659-67. doi: 10.1172/JCI36954. Epub 2009 May 18. J Clin Invest. 2009. PMID: 19451696 Free PMC article.
Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats.
Whitman DB, Cox CD, Breslin MJ, Brashear KM, Schreier JD, Bogusky MJ, Bednar RA, Lemaire W, Bruno JG, Hartman GD, Reiss DR, Harrell CM, Kraus RL, Li Y, Garson SL, Doran SM, Prueksaritanont T, Li C, Winrow CJ, Koblan KS, Renger JJ, Coleman PJ. Whitman DB, et al. Among authors: reiss dr. ChemMedChem. 2009 Jul;4(7):1069-74. doi: 10.1002/cmdc.200900069. ChemMedChem. 2009. PMID: 19418500
2-Aminobenzophenones as a novel class of bradykinin B1 receptor antagonists.
Su DS, Lim JL, Tinney E, Wan BL, Murphy KL, Reiss DR, Harrell CM, O'Malley SS, Ransom RW, Chang RS, Pettibone DJ, Yu J, Tang C, Prueksaritanont T, Freidinger RM, Bock MG, Anthony NJ. Su DS, et al. Among authors: reiss dr. J Med Chem. 2008 Jul 10;51(13):3946-52. doi: 10.1021/jm800199h. Epub 2008 Jun 14. J Med Chem. 2008. PMID: 18553956
Proline bis-amides as potent dual orexin receptor antagonists.
Bergman JM, Roecker AJ, Mercer SP, Bednar RA, Reiss DR, Ransom RW, Meacham Harrell C, Pettibone DJ, Lemaire W, Murphy KL, Li C, Prueksaritanont T, Winrow CJ, Renger JJ, Koblan KS, Hartman GD, Coleman PJ. Bergman JM, et al. Among authors: reiss dr. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1425-30. doi: 10.1016/j.bmcl.2008.01.001. Epub 2008 Jan 8. Bioorg Med Chem Lett. 2008. PMID: 18207395
Bradykinin B1 antagonists: biphenyl SAR studies in the cyclopropanecarboxamide series.
Kuduk SD, DiPardo RM, Chang RK, Di Marco CN, Murphy KL, Ransom RW, Reiss DR, Tang C, Prueksaritanont T, Pettibone DJ, Bock MG. Kuduk SD, et al. Among authors: reiss dr. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3608-12. doi: 10.1016/j.bmcl.2007.04.040. Epub 2007 Apr 24. Bioorg Med Chem Lett. 2007. PMID: 17482459
Potent bradykinin B1 receptor antagonists: 4-substituted phenyl cyclohexanes.
Su DS, Lim JL, Markowitz MK, Wan BL, Murphy KL, Reiss DR, Harrell CM, O'Malley SS, Ransom RW, Chang RS, Pettibone DJ, Tang C, Prueksaritanont T, Freidinger RM, Bock MG. Su DS, et al. Among authors: reiss dr. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3006-9. doi: 10.1016/j.bmcl.2007.03.059. Epub 2007 Mar 21. Bioorg Med Chem Lett. 2007. PMID: 17428657
Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.
Kuduk SD, Di Marco CN, Chang RK, Wood MR, Schirripa KM, Kim JJ, Wai JM, DiPardo RM, Murphy KL, Ransom RW, Harrell CM, Reiss DR, Holahan MA, Cook J, Hess JF, Sain N, Urban MO, Tang C, Prueksaritanont T, Pettibone DJ, Bock MG. Kuduk SD, et al. Among authors: reiss dr. J Med Chem. 2007 Jan 25;50(2):272-82. doi: 10.1021/jm061094b. J Med Chem. 2007. PMID: 17228869
Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.
Ransom RW, Harrell CM, Reiss DR, Murphy KL, Chang RS, Hess JF, Miller PJ, O'Malley SS, Hey PJ, Kunapuli P, Su DS, Markowitz MK, Wallace MA, Raab CE, Jones AN, Dean DC, Pettibone DJ, Freidinger RM, Bock MG. Ransom RW, et al. Among authors: reiss dr. Eur J Pharmacol. 2004 Sep 19;499(1-2):77-84. doi: 10.1016/j.ejphar.2004.07.104. Eur J Pharmacol. 2004. PMID: 15363953
Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.
Williams PD, Bock MG, Evans BE, Freidinger RM, Gallicchio SN, Guidotti MT, Jacobson MA, Kuo MS, Levy MR, Lis EV, Michelson SR, Pawluczyk JM, Perlow DS, Pettibone DJ, Quigley AG, Reiss DR, Salvatore C, Stauffer KJ, Woyden CJ. Williams PD, et al. Among authors: reiss dr. Bioorg Med Chem Lett. 1999 May 3;9(9):1311-6. doi: 10.1016/s0960-894x(99)00181-x. Bioorg Med Chem Lett. 1999. PMID: 10340620
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
Bell IM, Erb JM, Freidinger RM, Gallicchio SN, Guare JP, Guidotti MT, Halpin RA, Hobbs DW, Homnick CF, Kuo MS, Lis EV, Mathre DJ, Michelson SR, Pawluczyk JM, Pettibone DJ, Reiss DR, Vickers S, Williams PD, Woyden CJ. Bell IM, et al. Among authors: reiss dr. J Med Chem. 1998 Jun 4;41(12):2146-63. doi: 10.1021/jm9800797. J Med Chem. 1998. PMID: 9622556
1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.
Williams PD, Clineschmidt BV, Erb JM, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Pettibone DJ, Reiss DR, Veber DF, et al. Williams PD, et al. Among authors: reiss dr. J Med Chem. 1995 Nov 10;38(23):4634-6. doi: 10.1021/jm00023a002. J Med Chem. 1995. PMID: 7473590 No abstract available.
Identification of an orally active, nonpeptidyl oxytocin antagonist.
Pettibone DJ, Clineschmidt BV, Kishel MT, Lis EV, Reiss DR, Woyden CJ, Evans BE, Freidinger RM, Veber DF, Cook MJ, et al. Pettibone DJ, et al. Among authors: reiss dr. J Pharmacol Exp Ther. 1993 Jan;264(1):308-14. J Pharmacol Exp Ther. 1993. PMID: 8423533
A peripherally acting alpha-2 adrenoceptor antagonist: L-659,066.
Clineschmidt BV, Pettibone DJ, Lotti VJ, Hucker HB, Sweeney BM, Reiss DR, Lis EV, Huff JR, Vacca J. Clineschmidt BV, et al. Among authors: reiss dr. J Pharmacol Exp Ther. 1988 Apr;245(1):32-40. J Pharmacol Exp Ther. 1988. PMID: 2896239